Taurine chloramine inhibits proliferation of rheumatoid arthritis synoviocytes by triggering a p53-dependent pathway

Inflammation Research

Volumn 55, Issue 10, 2006, Pages 446-455

  Kontny, E ^a,b   Rudnicka, W ^a   Chorazy Massalska M ^a   Marcinkiewicz, J ^b   Maslinski W ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Inflammation; p53 tumor suppressor; Rheumatoid arthritis; Synoviocytes; Taurine chloramine

Indexed keywords

CYCLINE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PROTEIN P21; PROTEIN P53; SURVIVIN; TAURINE CHLORAMINE; TAURINE DERIVATIVE; THYMIDINE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL COUNT; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STIMULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IC 50; MALE; MITOSIS INHIBITION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; UPREGULATION; WESTERN BLOTTING;

EID: 33751107693     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-006-5067-5     Document Type: Article

References (60)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
2. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996; 39: 1781-90.
3. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest 1995; 96: 1631-8.
4. Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 2002; 61: 934-6.
5. Tanaka Y, Nomi M, Fujii K, Hubscher S, Maruo A, Matsumoto S et al. Intercellular adhesion molecule 1 underlies the functional heterogeneity of synovial cells in patients with rheumatoid arthritis: involvement of cell cycle machinery. Arthritis Rheum 2000; 43: 2513-22.
6. Helmchen B, Weckauf H, Ehemann V, Wittmann I, Meyer-Scholten C, Berger I. Expression pattern of cell cycle-related gene products in synovial stroma and synovial lining in active and quiescent stages of rheumatoid arthritis. Histol Histopathol 2005; 20: 365-72.
7. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25: 177-81.
8. Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 2004; 61: 822-42.
9. Taranto E, Xue JR, Lacey D, Hutchinson P, Smith M, Morand EF et al. Detection of the p53 regulator murine double-minute protein 2 in rheumatoid arthritis. J Rheumatol 2005; 32: 424-9.
10. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
11. Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci 2000; 57: 1613-36.
12. Boulaire J, Fotedar A, Fotedar R. The functions of the cdk-cyclin kinase inhibitor p21WAF1. Pathol Biol (Paris) 2000; 48: 190-202.
13. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000; 1471 : M43-56.
14. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13: 41-7.
15. Pagano M. Control of DNA synthesis and mitosis by the Skp2-p27-Cdk1/2 axis. Mol Cell 2004; 14: 414-6.
16. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol 2000; 183: 18-27.
17. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci 2003; 116: 3051-60.
18. Suzuki A, Hayashida M, Ito T, Kawano H, Nakano T, Miura M et al. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation. Oncogene 2000; 19: 3225-34.
19. Morita Y, Kashihara N, Yamamura M, Okamoto H, Harada S, Maeshima Y et al. Inhibition of rheumatoid synovial fibroblast proliferation by antisense oligonucleotides targeting proliferating cell nuclear antigen messenger RNA. Arthritis Rheum 1997; 40: 1292-7.
20. Chiou SK, Jones MK, Tarnawski AS. Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 2003; 9: PI25-9.
21. Shivakumar CV, Brown DR, Deb S, Deb SP. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 1995; 15: 6785-93.
22. Morris GF, Bischoff JR, Mathews MB. Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. Proc Natl Acad Sci U S A 1996; 93: 895-9.
23. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-57.
24. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-22.
25. Kontny E, Grabowska A, Kowalczewski J, Kurowska M, Janicka I, Marcinkiewicz J et al. Taurine chloramine inhibition of cell proliferation and cytokine production by rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum 1999; 42: 2552-60.
26. Kontny E, Szczepanska K, Kowalczewski J, Kurowska M, Janicka I, Marcinkiewicz J et al. The mechanism of taurine chloramine inhibition of cytokine (interleukin-6, interleukin-8) production by rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum 2000; 43: 2169-77.
27. Kontny E, Rudnicka W, Kowalczewski J, Marcinkiewicz J, Maslinski W. Selective inhibition of cyclooxygenase 2-generated prostaglandin E2 synthesis in rheumatoid arthritis synoviocytes by taurine chloramine. Arthritis Rheum 2003; 48: 1551-5.
28. Kontny E, Maslinski W, Marcinkiewicz J. Anti-inflammatory activities of taurine chloramine: implication for immunoregulation and pathogenesis of rheumatoid arthritis. Adv Exp Med Biol 2003; 526: 329-40.
29. Kontny E, Chorazy-Massalska M, Rudnicka W, Janicka I, Marcinkiewicz J, Maslinski W. The effect of taurine and its metabolites on the pathogenic functions of rheumatoid arthritis fibroblast-like synoviocytes. Centr Eur J Immunol 2003; 28: 167-72.
30. Schuller-Levis GB, Park E. Taurine: new implications for an old amino acid. FEMS Microbiol Lett 2003; 226: 195-202.
31. Weiss SJ, Klein R, Slivka A, Wei M. Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J Clin Invest 1982; 70: 598-607.
32. Davies EV, Williams BD, Campbell AK. Synovial fluid polymorphonuclear leucocytes from patients with rheumatoid arthritis have reduced MPO and NADPH-oxidase activity. Br J Rheumatol 1990; 29: 415-21.
33. Smith SC, Folefac VA, Osei DK, Revell PA. An immunocytochemical study of the distribution of proline-4-hydroxylase in normal, osteoarthritic and rheumatoid arthritic synovium at both the light and electron microscopic level. Br J Rheumatol 1998; 37: 287-91.
34. Gottardi W, Nagl M. Chemical properties of N-chlorotaurine sodium, a key compound in the human defence system. Arch Pharm (Weinheim) 2002; 335: 411-21.
35. Ferrari-Lacraz S, Zheng XX, Kim YS, Li Y, Maslinski W, Li XC et al. An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J Immunol 2001; 167: 3478-85.
36. Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999; 5: 760-7.
37. Kontny E, Ziolkowska M, Ryzewska A, Maslinski W. Protein kinase c-dependent pathway is critical for the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). Cytokine 1999; 11: 839-48.
38. Wedemeyer N, Gohde W, Potter T. Flow cytometric analysis of reverse transcription-PCR products: quantification of p21 (WAF1/CIP1) and proliferating cell nuclear antigen mRNA. Clin Chem 2000; 46: 1057-64.
39. Ikeguchi M, Ueta T, Yamane Y, Hirooka Y, Kaibara N. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma. Clin Cancer Res 2002; 8: 3131-6.
40. Qu Z, Garcia CH. O'Rourke LM, Planck SR, Kohli M, Rosenbaum JT. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthritis Rheum 1994; 37: 212-20.
41. Park E, Jia J, Quinn MR, Schuller-Levis G. Taurine chloramine inhibits lymphocyte proliferation and decreases cytokine production in activated human leukocytes. Clin Immunol 2002; 102: 179-84.
42. Emerson DK, McCormick ML, Schmidt JA, Knudson CM. Taurine monochloramine activates a cell death pathway involving Bax and Caspase-9. J Biol Chem 2005; 280: 3233-41.
43. Vile GF, Rothwell LA, Kettle AJ. Initiation of rapid, P53-dependent growth arrest in cultured human skin fibroblasts by reactive chlorine species. Arch Biochem Biophys 2000; 377: 122-8.
44. Kontny E C-MM, Rudnicka W, Marcinkiewicz J, Maslinski W. Cytotoxicity of taurine metabolites depends on the cell type. Adv Exp Med Biol 2006; 583: in press.
45. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-102.
46. Muller-Ladner U, Nishioka K. p53 in rheumatoid arthritis: friend or foe? Arthritis Res 2000; 2: 175-8.
47. Sun Y, Cheung HS. p53, proto-oncogene and rheumatoid arthritis. Semin Arthritis Rheum 2002; 31: 299-310.
48. Pap T, Aupperle KR, Gay S, Firestein GS, Gay RE. Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheum 2001; 44: 676-81.
49. Yao Q, Wang S, Glorioso JC, Evans CH, Robbins PD, Ghivizzani SC et al. Gene transfer of p53 to arthritic joints stimulates synovial apoptosis and inhibits inflammation. Mol Ther 2001; 3: 901-10.
50. Yamanishi Y, Boyle DL, Pinkoski MJ, Mahboubi A, Lin T, Han Z et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am J Pathol 2002; 160: 123-30.
51. Nonomura Y, Kohsaka H, Nasu K, Terada Y, Ikeda M, Miyasaka N. Suppression of arthritis by forced expression of cyclin-dependent kinase inhibitor p21(Cip1) gene into the joints. Int Immunol 2001; 13: 723-31.
52. Nonomura Y, Kohsaka H, Nagasaka K, Miyasaka N. Gene transfer of a cell cycle modulator exerts anti-inflammatory effects in the treatment of arthritis. J Immunol 2003; 171: 4913-9.
53. Cha HS, Rosengren S, Boyle DL, Firestein GS. PUMA regulation and proapoptotic effects in fibroblast-like synoviocytes. Arthritis Rheum 2006; 54: 587-92.
54. Migita K, Tanaka F, Yamasaki S, Shibatomi K, Ida H, Kawakami A et al. Regulation of rheumatoid synoviocyte proliferation by endogenous p53 induction. Clin Exp Immunol 2001; 126: 334-8.
55. Perlman H, Bradley K, Liu H, Cole S, Shamiyeh E, Smith RC et al. IL-6 and matrix metalloproteinase-1 are regulated by the cyclin-dependent kinase inhibitor p21 in synovial fibroblasts. J Immunol 2003; 170: 838-45.
56. Miyamoto Y, Kanayama A, Inoue J, Konishi YS, Shimizu M. Taurine is involved in oxidation of IkappaB alpha at Met45: N-halogenated taurine and anti-inflammatory action. Adv Exp Med Biol 2003; 526: 373-80.
57. Kwasny-Krochin B, Bobek M, Kontny E, Gluszko P, Biedron R, Chain BM et al. Effect of taurine chloramine, the product of activated neutrophils, on the development of collagen-induced arthritis in DBA 1/J mice. Amino Acids 2002; 23: 419-26.
58. Trang LE, Furst P, Odeback AC, Lovgren O. Plasma amino acids in rheumatoid arthritis. Scand J Rheumatol 1985; 14: 393-402.
59. Rylance HJ. Hypertaurinuria in rheumatoid arthritis. Ann Rheum Dis 1969; 28: 41-4.
60. Kontny E, Wojtecka LE, Rell-Bakalarska K, Dziewczopolski W, Maslinski W, Maslinski S. Impaired generation of taurine chloramine by synovial fluid neutrophils of rheumatoid arthritis patients. Amino Acids 2002; 23: 415-8.